600085 Stock Overview
Engages in the scientific research, production, distribution, and sale of Chinese medicines in China and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 1/6 |
| Past Performance | 3/6 |
| Financial Health | 4/6 |
| Dividends | 3/6 |
Beijing Tongrentang Co., Ltd Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥33.65 |
| 52 Week High | CN¥55.74 |
| 52 Week Low | CN¥33.38 |
| Beta | 0.21 |
| 11 Month Change | -8.56% |
| 3 Month Change | -23.85% |
| 1 Year Change | -38.71% |
| 33 Year Change | 0.42% |
| 5 Year Change | 20.18% |
| Change since IPO | 1,131.79% |
Recent News & Updates
Beijing Tongrentang's (SHSE:600085) Profits May Not Reveal Underlying Issues
Sep 06
Earnings Miss: Beijing Tongrentang Co., Ltd Missed EPS By 20% And Analysts Are Revising Their Forecasts
Sep 03Here's Why Beijing Tongrentang (SHSE:600085) Has Caught The Eye Of Investors
Aug 17Is Beijing Tongrentang (SHSE:600085) Using Too Much Debt?
Jul 15Recent updates
Beijing Tongrentang's (SHSE:600085) Profits May Not Reveal Underlying Issues
Sep 06Earnings Miss: Beijing Tongrentang Co., Ltd Missed EPS By 20% And Analysts Are Revising Their Forecasts
Sep 03Here's Why Beijing Tongrentang (SHSE:600085) Has Caught The Eye Of Investors
Aug 17Is Beijing Tongrentang (SHSE:600085) Using Too Much Debt?
Jul 15Beijing Tongrentang Co., Ltd (SHSE:600085) Shares Could Be 21% Below Their Intrinsic Value Estimate
Jun 09Unpleasant Surprises Could Be In Store For Beijing Tongrentang Co., Ltd's (SHSE:600085) Shares
Apr 16If EPS Growth Is Important To You, Beijing Tongrentang (SHSE:600085) Presents An Opportunity
Mar 31Beijing Tongrentang (SHSE:600085) Seems To Use Debt Rather Sparingly
Feb 29Shareholder Returns
| 600085 | CN Pharmaceuticals | CN Market | |
|---|---|---|---|
| 7D | -3.0% | -1.7% | -2.4% |
| 1Y | -38.7% | -10.7% | -20.1% |
Return vs Industry: 600085 underperformed the CN Pharmaceuticals industry which returned -10.7% over the past year.
Return vs Market: 600085 underperformed the CN Market which returned -20.1% over the past year.
Price Volatility
| 600085 volatility | |
|---|---|
| 600085 Average Weekly Movement | 4.2% |
| Pharmaceuticals Industry Average Movement | 5.1% |
| Market Average Movement | 5.4% |
| 10% most volatile stocks in CN Market | 8.6% |
| 10% least volatile stocks in CN Market | 3.6% |
Stable Share Price: 600085's share price has been volatile over the past 3 months.
Volatility Over Time: 600085's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1997 | 16,777 | Chaohua Zhang | gf.tongrentang.com |
Beijing Tongrentang Co., Ltd engages in the scientific research, production, distribution, and sale of Chinese medicines in China and internationally. The company provides product formulations, such as pills, powders, liquors, capsules, oral liquids, and dripping pills in the areas of cardiovascular, gynecology, heat clearing class, respiratory system, tonic and soothe the nerves, digestive system, pediatrics, expelling wind and dampness, orthopedics, five senses, skin surgery, spiritual, and food alcohol diseases. It sells its products under the brand names of Angong Niuhuang series, Tongren Niuhuang Qingxin series, Tongren Dahuoluo series, Yufeng Ningxin dripping pills, Piantan Fuxing pills, etc. The company was founded in 1997 and is headquartered in Beijing, China.
Beijing Tongrentang Co., Ltd Fundamentals Summary
| 600085 fundamental statistics | |
|---|---|
| Market cap | CN¥46.90b |
| Earnings (TTM) | CN¥1.70b |
| Revenue (TTM) | CN¥17.86b |
27.1x
P/E Ratio2.6x
P/S RatioIs 600085 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 600085 income statement (TTM) | |
|---|---|
| Revenue | CN¥17.86b |
| Cost of Revenue | CN¥9.78b |
| Gross Profit | CN¥8.08b |
| Other Expenses | CN¥6.38b |
| Earnings | CN¥1.70b |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.24 |
| Gross Margin | 45.26% |
| Net Profit Margin | 9.54% |
| Debt/Equity Ratio | 11.7% |
How did 600085 perform over the long term?
See historical performance and comparison